In most clinical trials for PD-1/PD-L1 ICIs, liver cancer patients with HBV infection were required to have a baseline HBV load <100 IU/mL for eligibility; therefore, the effect of baseline viral load on clinical outcomes could not be assessed. This evidence concerns the gene CD274 and liver cancer.